Rule-Based High-Risk Flu
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorGeisinger Clinic
About this trial
Previous work by the study team has shown that informing patients of their high risk of flu and flu-related complications increases their likelihood of getting a flu shot (Rosenbaum et al., 2026). In this work, an artificial intelligence (AI)-based algorithm determined which patients were at high risk for flu. This year, the team will test whether risk messages remain effective when a non-algorithmic rule-based additive risk index (McGovern et al., 2024) is used to identify patients at high risk.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age 18 or older
Has four or more CDC risk factors for influenza reflected in EHR data
Has a primary care physician employed by Geisinger
Attended at least one appointment at Geisinger between 7/17/2024 and 7/16/2026
Disqualifiers
None
Trial design
Design model
Parallel
Treatments tested in this trial
Risk reduction
BehavioralMailed letter, patient portal message and/or text message
Treatment groups
51,215 Participants
are divided into 2 treatment groupsGroup A: ControlNo intervention 0 interventions
Group B: High-risk outreachExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Flu vaccination (y/n)
Flu vaccine documented in the electronic health record
Time frame
In the 29 days following the date the first messages were sentSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: